Peripheral artery disease (PAD) is increasingly prevalent and leads to disability and high cardiovascular risk. The determinants of clinical status and prognosis in PAD are not well understood. Emerging evidence from experimental models identifies microRNAs (miRNAs) as regulators of cellular responses to limb ischemia and as potential therapeutic targets. Altered miRNA expression may contribute to PAD by modulating angiogenesis, inflammation and endothelial injury response, but little is known about these mechanisms in patients. MiRNAs circulate in the blood, hold potential as biomarkers, and may function as endocrine signaling factors. Endothelial cells are a potential source for circulating miRNA. We have developed methods to perform comprehensive quantitative RT-PCR based miRNA profiling in plasma. In addition, we have established the ability to characterize miRNA expression in freshly isolated endothelial cells. The proposed research aims to define circulating and arterial endothelial miRNAs in PAD to provide insight into the mechanisms driving clinical disease in PAD. We will accomplish Aims 1 and 2 by studying our well-characterized, National Heart Lung and Blood Institute-funded PAD cohort and controls (306 PAD patients, 50 CAD patients and 50 controls) with longitudinal outcome evaluation and Aim 3 by enrolling 90 patients (30 each PAD, CAD alone and control) for endothelial cell isolation.
In Aim 1, we will test the hypothesis that PAD alters circulating miRNA expression by comparing PAD patients to CAD and healthy controls.
In Aim 2, we will relate circulating miRNAs to disease severity, inflammatory cytokines, and circulating angiogenesis modulators in PAD. Further, we will use previously collected 2-year follow-up data to test the hypothesis that circulating miRNAs are associated with coronary and peripheral disease events in PAD.
In Aim 3, we will collect arterial endothelial cells at the time of angiography by J-wire biopsy from the iliofemoral arteries. We relate endothelial cell miRNA expression to circulating miRNAs and PAD status. These studies will provide new information regarding circulating and endothelial miRNAs in PAD and may stimulate innovative treatment strategies.

Public Health Relevance

Peripheral arterial disease (PAD) affects over 8 million Americans and leads to physical disability, limb amputation, heart attack and stroke. The determinants of the clinical status and prognosis in PAD are not well understood. This application focuses on microRNAs to understand the mechanisms of cardiovascular risk in PAD and may generate novel therapeutic approaches for PAD.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL109790-01A1
Application #
8301065
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Reid, Diane M
Project Start
2012-04-01
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
1
Fiscal Year
2012
Total Cost
$220,873
Indirect Cost
$65,697
Name
Boston University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Fetterman, Jessica L; Liu, Chunyu; Mitchell, Gary F et al. (2018) Relations of mitochondrial genetic variants to measures of vascular function. Mitochondrion 40:51-57
Fetterman, Jessica L; Holbrook, Monica; Westbrook, David G et al. (2016) Mitochondrial DNA damage and vascular function in patients with diabetes mellitus and atherosclerotic cardiovascular disease. Cardiovasc Diabetol 15:53
Fetterman, Jessica L; Holbrook, Monica; Flint, Nir et al. (2016) Restoration of autophagy in endothelial cells from patients with diabetes mellitus improves nitric oxide signaling. Atherosclerosis 247:207-17
Hamburg, Naomi M (2015) Late arterial waves: an early warning system for heart failure? J Am Heart Assoc 4:e001805
Hamburg, Naomi M; Leeper, Nicholas J (2015) Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease. Curr Vasc Pharmacol 13:316-23
Kikuchi, Ryosuke; Nakamura, Kazuto; MacLauchlan, Susan et al. (2014) An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat Med 20:1464-71
Farb, Melissa G; Tiwari, Stephanie; Karki, Shakun et al. (2014) Cyclooxygenase inhibition improves endothelial vasomotor dysfunction of visceral adipose arterioles in human obesity. Obesity (Silver Spring) 22:349-55
Ngo, Doan T M; Farb, Melissa G; Kikuchi, Ryosuke et al. (2014) Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation 130:1072-80
Kiani, Soroosh; Aasen, Jonathan G; Holbrook, Monika et al. (2013) Peripheral artery disease is associated with severe impairment of vascular function. Vasc Med 18:72-8
Tabit, Corey E; Shenouda, Sherene M; Holbrook, Monica et al. (2013) Protein kinase C-? contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 127:86-95

Showing the most recent 10 out of 12 publications